Publication: Circulating miRNAs signature on breast cancer: the MCC-Spain project
| dc.contributor.author | Gómez-Acebo, Inés | |
| dc.contributor.author | Llorca, Javier | |
| dc.contributor.author | Alonso-Molero, Jéssica | |
| dc.contributor.author | Díaz-Martínez, Marta | |
| dc.contributor.author | Perez-Gomez, Beatriz | |
| dc.contributor.author | Amiano, Pilar | |
| dc.contributor.author | Belmonte, Thalia | |
| dc.contributor.author | Molina, Antonio J | |
| dc.contributor.author | Burgui, Rosana | |
| dc.contributor.author | Castaño-Vinyals, Gemma | |
| dc.contributor.author | Moreno, Victor | |
| dc.contributor.author | Molina-Barceló, Ana | |
| dc.contributor.author | Marcos-Gragera, Rafael | |
| dc.contributor.author | Kogevinas, Manolis | |
| dc.contributor.author | Pollan-Santamaria, Marina | |
| dc.contributor.author | Dierssen-Sotos, Trinidad | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | |
| dc.contributor.funder | Fundación Marqués de Valdecilla | |
| dc.contributor.funder | International Cancer Genome Consortium | |
| dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
| dc.contributor.funder | Red Temática de Investigación Cooperativa en Cáncer (RTICC) (España) | |
| dc.contributor.funder | Junta de Castilla y León (España) | |
| dc.contributor.funder | Regional Government of Andalusia (España) | |
| dc.contributor.funder | Generalitat Valenciana (España) | |
| dc.contributor.funder | Fundación La Caixa | |
| dc.contributor.funder | Basque Government (España) | |
| dc.contributor.funder | Gobierno de la Región de Murcia (España) | |
| dc.contributor.funder | Asociación Española Contra el Cáncer | |
| dc.contributor.funder | Government of Catalonia (España) | |
| dc.contributor.funder | Agència de Gestió d´Ajuts Universitaris i de Recerca (AGAUR) | |
| dc.contributor.funder | Fundación Caja de Ahorros de Asturias | |
| dc.contributor.funder | University of Oviedo (España) | |
| dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | |
| dc.contributor.funder | Ministerio de Economía (España) | |
| dc.contributor.funder | Unión Europea. Comisión Europea | |
| dc.date.accessioned | 2023-11-14T10:11:46Z | |
| dc.date.available | 2023-11-14T10:11:46Z | |
| dc.date.issued | 2023-11-04 | |
| dc.description.abstract | Purpose: To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. Method: miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. Results: The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. Conclusion: We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, and PI17/01388, PI18/00171), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOODCT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship. | es_ES |
| dc.format.number | 1 | es_ES |
| dc.format.page | 480 | es_ES |
| dc.format.volume | 28 | es_ES |
| dc.identifier.citation | Eur J Med Res. 2023 Nov 4;28(1):480. | es_ES |
| dc.identifier.doi | 10.1186/s40001-023-01471-2 | es_ES |
| dc.identifier.e-issn | 2047-783X | es_ES |
| dc.identifier.journal | European journal of medical research | es_ES |
| dc.identifier.pubmedID | 37925534 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/16661 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | BioMed Central (BMC) | |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0036/ES/Cáncer/ | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CEX2018-000806-S | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PRE2019-089038 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/1770 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/0533 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI08/1359 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PS09/00773 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PS09/01286 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PS09/01903 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PS09/02078 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PS09/01662 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2011) (2011)/PI11/01889 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2011) (2011)/PI11/02213 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2012) (2012)/PI12/00488 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2012) (2012)/PI12/01270 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2012) (2012)/PI12/00715 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/null/null/Subprograma de proyectos de investigacion en salud (AES 2014). Modalidad proyectos en salud. (2014)/PI14/01219 | es_ES |
| dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI14/0613 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI17 - Proyectos de investigacion en salud (AES 2017). Modalidad proyectos en salud. (2017)/PI17/01388 | es_ES |
| dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00171 | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/FOODCT-2006-036224-HIWATE | es_ES |
| dc.relation.publisherversion | https://doi.org/10.1186/s40001-023-01471-2 | es_ES |
| dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
| dc.repisalud.institucion | ISCIII | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Atribución 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | Breast cancer | es_ES |
| dc.subject | Screening | es_ES |
| dc.subject | miRNA | es_ES |
| dc.subject | Diagnosis | es_ES |
| dc.subject | Prognosis | es_ES |
| dc.subject.mesh | Circulating MicroRNA | es_ES |
| dc.subject.mesh | Breast Neoplasms | es_ES |
| dc.subject.mesh | MicroRNAs | es_ES |
| dc.subject.mesh | Humans | es_ES |
| dc.subject.mesh | Female | es_ES |
| dc.subject.mesh | Spain | es_ES |
| dc.subject.mesh | Gene Expression Profiling | es_ES |
| dc.subject.mesh | Biomarkers, Tumor | es_ES |
| dc.subject.mesh | ROC Curve | es_ES |
| dc.title | Circulating miRNAs signature on breast cancer: the MCC-Spain project | es_ES |
| dc.type | research article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 4b7eabf1-df99-4684-9c92-42bc37de6a41 | |
| relation.isAuthorOfPublication | 57cdf9f1-5836-41aa-9880-cf773b0e65f9 | |
| relation.isAuthorOfPublication | cb3b77d8-c78c-4238-9b9d-c1171ff3ab51 | |
| relation.isAuthorOfPublication.latestForDiscovery | 4b7eabf1-df99-4684-9c92-42bc37de6a41 | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | efa64f05-b985-4984-8f1e-5fc4ef21f502 | |
| relation.isFunderOfPublication | 65f5f3a7-1937-4dbd-aa46-55df595bfa5d | |
| relation.isFunderOfPublication | 9f6bc58f-51f7-48ec-a642-79dc5e524322 | |
| relation.isFunderOfPublication | 77b2fc20-6311-4e46-98a7-83e46257b93b | |
| relation.isFunderOfPublication | 3fb2c806-a1bc-429e-99df-4c2e50f8a129 | |
| relation.isFunderOfPublication | d1a8e7e7-3324-4d09-b435-4b96717a7edf | |
| relation.isFunderOfPublication | a16348d3-7483-4017-92f4-0f4f47980d57 | |
| relation.isFunderOfPublication | 842e6617-7822-4501-a927-7e8cedda4aa6 | |
| relation.isFunderOfPublication | f04d23ec-a91d-4242-88b0-cc436888f8a2 | |
| relation.isFunderOfPublication | 6b0fdff7-65d0-4c97-9d9f-0ddb2b20aabe | |
| relation.isFunderOfPublication | c6d15272-88a9-499b-9579-6f7e25795a56 | |
| relation.isFunderOfPublication | 453a1189-9bca-4be8-8d60-695f50fe028b | |
| relation.isFunderOfPublication | c6fbffec-abb4-4f0e-81e0-3b254d5dd85d | |
| relation.isFunderOfPublication | af365449-d1bb-4678-af42-7483b561cd83 | |
| relation.isFunderOfPublication | 937e1afd-baa0-4b8f-89fe-063355acebb1 | |
| relation.isFunderOfPublication | d94cc2da-aec2-4350-9f43-b1eb7dafa34f | |
| relation.isFunderOfPublication | 9bec53f6-b1d2-4340-9f6b-91815956d602 | |
| relation.isFunderOfPublication | ca7182dc-aaab-45ec-a09d-755563fe05f2 | |
| relation.isFunderOfPublication | 639cecfa-9455-4e7f-9f65-9ece17a878f0 | |
| relation.isFunderOfPublication.latestForDiscovery | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isPublisherOfPublication | 4fe896aa-347b-437b-a45b-95f4b60d9fd3 | |
| relation.isPublisherOfPublication.latestForDiscovery | 4fe896aa-347b-437b-a45b-95f4b60d9fd3 |
Files
Original bundle
1 - 4 of 4
Loading...
- Name:
- Circulating_miRNAs_SignatureBreastCancer_2023.pdf
- Size:
- 1.88 MB
- Format:
- Adobe Portable Document Format
- Description:
- Articulo
Loading...
- Name:
- Supplementary1_Circulating_miRNAs_SignatureBreastCancer_2023.tif
- Size:
- 206.33 KB
- Format:
- Tag Image File Format
- Description:
- Supplementary material 1
Loading...
- Name:
- Supplementary2_Circulating_miRNAs_SignatureBreastCancer_2023.tif
- Size:
- 57.06 KB
- Format:
- Tag Image File Format
- Description:
- Supplementary material 2
Loading...
- Name:
- Supplementary3_Circulating_miRNAs_SignatureBreastCancer_2023.pdf
- Size:
- 648.36 KB
- Format:
- Adobe Portable Document Format
- Description:
- Supplementary material 3
Collections
Centro Nacional de Epidemiología (CNE)
IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña)
IDIVAL - Instituto de Investigación Marqués de Valdecilla (Cantabria)
IIS BioGipuzkoa - Asociación Instituto de Investigación Sanitaria BioGipuzkoa (País Vasco)
IMIM - Hospital del Mar Research Institute-Barcelona (Cataluña)
ISPA - Instituto de Investigación Sanitaria del Principado de Asturias (Asturias)
IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña)
IDIVAL - Instituto de Investigación Marqués de Valdecilla (Cantabria)
IIS BioGipuzkoa - Asociación Instituto de Investigación Sanitaria BioGipuzkoa (País Vasco)
IMIM - Hospital del Mar Research Institute-Barcelona (Cataluña)
ISPA - Instituto de Investigación Sanitaria del Principado de Asturias (Asturias)


